Update on pruritic mechanisms of hypertrophic scars in postburn patients: The potential role of opioids and their receptors

Journal of Burn Care and Research

Volumn 32, Issue 4, 2011, Pages

  Cheng, Biao ^a   Liu, Hong Wei ^b   Fu, Xiao Bing ^c  

^a GUANGZHOU GENERAL HOSPITAL OF GUANGZHOU MILITARY COMMAND   (China)

^b JINAN UNIVERSITY   (China)

^c Institute for Basic Research   (China)

Author keywords

[No Author keywords available]

Indexed keywords

17 METHYLNALTREXONE; 3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE METHANESULFONATE; 4 [ALPHA (4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 METHOXYBENZYL] N,N DIETHYLBENZAMIDE; ALFENTANIL; ANTIHISTAMINIC AGENT; CLOCINNAMOX; DIPHENHYDRAMINE; FENTANYL; HISTAMINE RECEPTOR; MORPHINE; NALTREXONE; NEUROKININ 1 RECEPTOR; NEUROKININ 2 RECEPTOR; NORBINALTORPHIMINE; OPIATE ANTAGONIST; OPIATE RECEPTOR; PLACEBO; REMIFENTANIL; SUBSTANCE P RECEPTOR;

ANALGESIA; ARTICLE; BURN PATIENT; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE SEVERITY; DOSE RESPONSE; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; HISTAMINE RELEASE; HUMAN; HYPERTROPHIC SCAR; INFLAMMATION; NERVE ENDING; OUTCOME ASSESSMENT; PAIN; PAIN ASSESSMENT; PATHOGENESIS; PRURITUS; QUALITY OF LIFE; TREATMENT INDICATION; TREATMENT PLANNING; TREATMENT RESPONSE; WOUND HEALING;

ANALGESICS; BURNS; CHOLESTASIS; CICATRIX, HYPERTROPHIC; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; NEURAL PATHWAYS; PRURITUS; RECEPTORS, NEUROKININ-1; RECEPTORS, OPIOID;

EID: 79960825655     PISSN: 1559047X     EISSN: 15590488     Source Type: Journal    
DOI: 10.1097/BCR.0b013e3182223c32     Document Type: Article

References (71)

1. Van Loey NE, Bremer M, Faber AW, Middelkoop E, Nieu-wenhuis MK. Itching following burns: epidemiology and predictors. Br J Dermatol 2008;158:95-100. (Pubitemid 350225550)
2. Forbes-Duchart L, Cooper J, Nedelec B, Ross L, Quanbury A. Burn therapists' opinion on the application and essential characteristics of a burn scar outcome measure. J Burn Care Res 2009;30:792-800.
3. Yosipovitch G, Samuel LS. Neuropathic and psychogenic itch. Dermatol Ther 2008;21:32-41. (Pubitemid 351343786)
4. Brooks JP, Malic CC, Judkins KC. Scratching the surface- managing the itch associated with burns: a review of current knowledge. Burns 2008;34:751-60.
5. Cheng B, Liu HW, Fu XB, Sheng ZY, Li JF. Coexistence and upregulation of three types of opioid receptors, mu, delta and kappa, in human hypertrophic scars. Br J Dermatol 2008; 158:713-20. (Pubitemid 351415747)
6. Bigliardi PL, Tobin DJ, Gaveriaux-Ruff C, Bigliardi-Qi M. Opioids and the skin-where do we stand? Exp Dermatol 2009;18:424-30.
7. Hafenreffer S. Nosodochium, in quo cutis, eique adaeren-tium partium, affectus omnes, singulari methodo, et cogno-scendi e curandi fidelisime traduntur. Ulm: Kuhnen; 1660.
8. Reich A, Szepietowski JC. Opioid-induced pruritus: an update. Clin Exp Dermatol 2010;35:2-6.
9. Schmelz M. How pain becomes itch. Pain 2009;144:14-5.
10. Ikoma A, Steinhoff M, Stander S, Yosipovitch G, Schmelz M. The neurobiology of itch. Nat Rev Neurosci 2006;7:535-47. (Pubitemid 43995431)
11. Sun YG, Zhao ZQ, Meng XL, Yin J, Liu XY, Chen ZF. Cellular basis of itch sensation. Science 2009;325:1531-4
12. Ward L, Wright E, McMahon SB. Acomparison of the effects of noxious and innocuous counterstimuli on experimentally induced itch and pain. Pain 1996;64:129-38. (Pubitemid 26062250)
13. Bigliardi-Qi M, Lipp B, Sumanovski LT, Buechner SA, Big-liardi PL. Changes of epidermal mu-opiate receptor expression and nerve endings in chronic atopic dermatitis. Dermatology 2005;210:91-9. (Pubitemid 40463197)
14. Nelson RD. Postburn itch. In: Yosipovitch G, Greaves MW, Fleischer AB, McGlone F, editors. Itch: basic mechanism and therapy. New York: Marcel Dekker; 2004. p. 247-54.
15. Nakamura M, Toyoda M, Morohashi M. Pruritogenic mediators in psoriasis vulgaris: comparative evaluation of itch-associated cutaneous factors. Br J Dermatol 2003;149: 718-30. (Pubitemid 37411991)
16. Steinhoff M, Bienenstock J, Schmelz M, Maurer M, Wei E, Biro T. Neurophysiological, neuroimmunological, and neu-roendocrine basis of pruritus. J Invest Dermatol 2006;126: 1705-18. (Pubitemid 44102116)
17. Baker RA, Zeller RA, Klein RL, et al. Burn wound itch control using H1 and H2 antagonists. J Burn Care Rehabil 2001; 22:263-8. (Pubitemid 32701618)
18. Goutos I. Burns pruritus-a study of current practices in the UK. Burns 2010;36:42-8.
19. Ekblom A, Lundeberg T, Wahlgren CF. Influence of cal-citonin gene-related peptide on histamine- and substance P-induced itch, flare and weal in humans. Skin Pharmacol 1993;6:215-22. (Pubitemid 23308142)
20. Krishnaswamy G, Ajitawi O, Chi DS. The human mast cell: an overview. Methods Mol Biol 2006;315:13-34.
21. Harvima IT, Nilsson G, Naukkarinen A. Role of mast cells and sensory nerves in skin inflammation. G Ital Dermatol Venereol 2010;145:195-204.
22. Schmelz M, Schmidt R, Weidner C, Hilliges M, Torebjork HE, Handwerker HO. Chemical response pattern of different classes of C-nociceptors to pruritogens and algogens. J Neurophysiol 2003;89:2441-8. (Pubitemid 36570208)
23. Shim WS, Oh U. Histamine-induced itch and its relationship with pain. Mol Pain 2008;4:29.
24. Stander S, Steinhoff M, Schmelz M, Weisshaar E, Metze D, Luger T. Neurophysiology of pruritus: cutaneous elicitation of itch. Arch Dermatol 2003;139:1463-70. (Pubitemid 37441284)
25. Hagermark O, Strandberg K, Gronneberg R. Effects of his-tamine receptor antagonists on histamine-induced responses in human skin. Acta Derm Venereol 1979;59:297-300. (Pubitemid 9230088)
26. Krause L, Shuster S. Mechanism of action of antipruritic drugs. Br Med J (Clin Res Ed) 1983;287:1199-200. (Pubitemid 13014062)
27. Bell JK, McQueen DS, Rees JL. Involvement of histamine H4 and H1 receptors in scratching induced by histamine receptor agonists in Balb C mice. Br J Pharmacol 2004;142: 374-80. (Pubitemid 38750189)
28. Summey BT Jr, Yosipovitch G. Pharmacologic advances in the systemic treatment of itch. Dermatol Ther 2005;18: 328-32. (Pubitemid 41801852)
29. Hossen MA, InoueT,ShinmeiY, FujiiY,Watanabe T,Kamei C. Role of substance P on histamine H(3) antagonist-induced scratching behavior in mice. J Pharmacol Sci 2006; 100:297-302.
30. Hofstra CL, Desai PJ, Thurmond RL, Fung-Leung WP. His-tamine H4 receptor mediates chemotaxis and calcium mobilization of mast cells. J Pharmacol Exp Ther 2003;305: 1212-21. (Pubitemid 36618001)
31. Biro T, Ko MC, Bromm B, et al. How best to fight that nasty itch-from new insights into the neuroimmunological, neu-roendocrine, and neurophysiological bases of pruritus to novel therapeutic approaches. Exp Dermatol 2005;14: 225-40. (Pubitemid 40394206)
32. Shimizu S, Tanaka H, Sakaki S, Yukioka T, Matsuda H, Shimazaki S. Burn depth affects dermal interstitial fluid pressure, free radical production, and serum histamine levels in rats. J Trauma 2002;52:683-7. (Pubitemid 34437227)
33. Lindblom L, Cassuto J, Yregård L, Tarnow P, Räntfors J, Löwhagen Hendén P. Role of vasoactive intestinal polypep-tide in burn-induced oedema formation. Burns 2000;26: 443-8. (Pubitemid 30254174)
34. Lofgren O, Qi Y, Lundeberg T. Inhibitory effects of tachy-kinin receptor antagonists on thermally induced inflammatory reactions in a rat model. Burns 1999;25:125-9. (Pubitemid 29134667)
35. Dunnick CA, Gibran NS, Heimbach DM. Substance P has a role in neurogenic mediation of human burn wound healing. J Burn Care Rehabil 1996;17:390-6. (Pubitemid 26329714)
36. Santos FX, Arroyo C, Garcia I, et al. Role of mast cells in the pathogenesis of postburn inflammatory response: reactive oxygen species as mast cell stimulators. Burns 2000;26:145-7. (Pubitemid 30050607)
37. LaSalle L, Rachelska G, Nedelec B. Naltrexone for the management of post-burn pruritus: a preliminary report. Burns 2008;34:797-802.
38. Henderson J, Terenghi G, McGrouther DA, Ferguson MW. The reinnervation pattern of wounds and scars may explain their sensory symptoms. J Plast Reconstr Aesthet Surg 2006; 59:942-50.
39. Cheng B, Liu HW, Fu XB, Sheng ZY, Qiu JY, Cao R. [Expression of beta-endorphin and micro-opioid receptor during wound healing process in rat with deep partial-thickness scald]. Zhonghua Shao Shang Za Zhi 2007;23:36-9. (Pubitemid 46738991)
40. Silverman SM. Opioid induced hyperalgesia: clinical implications for the pain practitioner. Pain Physician 2009;12: 679-84.
41. Tegeder I, Meier S, Burian M, Schmidt H, Geisslinger G, Lotsch J. Peripheral opioid analgesia in experimental human pain models. Brain 2003;126(Pt 5):1092-102. (Pubitemid 36522952)
42. Watterson G, Howard R, Goldman A. Peripheral opioids in inflammatory pain. Arch Dis Child 2004;89:679-81.
43. Atanassoff PG, Brull SJ, Zhang J, Greenquist K, Silverman DG, Lamotte RH. Enhancement of experimental pruritus and mechanically evoked dysesthesiae with local anesthesia. Somatosens Mot Res 1999;16:291-8. (Pubitemid 30006504)
44. Brull SJ, Atanassoff PG, Silverman DG, Zhang J, Lamotte RH. Attenuation of experimental pruritus and mechanically evoked dysesthesiae in an area of cutaneous allodynia. So-matosens Mot Res 1999;16:299-303. (Pubitemid 30006505)
45. Yosipovitch G, Fast K, Bernhard JD. Noxious heat and scratching decrease histamine-induced itch and skin blood flow. J Invest Dermatol 2005;125:1268-72.
46. Ikoma A, Fartasch M, Heyer G, Miyachi Y, Handwerker H, Schmelz M. Painful stimuli evoke itch in patients with chronic pruritus: central sensitization for itch. Neurology 2004;62: 212-7. (Pubitemid 38167127)
47. Szarvas S, Harmon D, Murphy D. Neuraxial opioid-induced pruritus: a review. J Clin Anesth 2003;15:234-9. (Pubitemid 36593453)
48. Andrew D, Schmelz M, Ballantyne JC. Itch-mechanisms and mediators. In: Pipra, editor. Management. Seattle: IASP Press; 2003.
49. Heyer G, Dotzer M, Diepgen TL, Handwerker HO. Opiate and H1 antagonist effects on histamine induced pruritus and alloknesis. Pain 1997;73:239-43. (Pubitemid 27491686)
50. McRae CA, Prince MI, HudsonM, Day CP, James OF, Jones DE. Pain as a complication of use of opiate antagonists for symptom control in cholestasis. Gastroenterology 2003;125: 591-6. (Pubitemid 36929440)
51. Jones EA, Neuberger J, Bergasa NV. Opiate antagonist therapy for the pruritus of cholestasis: the avoidance of opioid withdrawal-like reactions. QJM 2002;95:547-52. (Pubitemid 34919145)
52. Kamei J, Nagase H. Norbinaltorphimine, a selective kappa-opioid receptor antagonist, induces an itch-associated response in mice. Eur J Pharmacol 2001;418:141-5. (Pubitemid 32378821)
53. Kjellberg F, Tramer MR. Pharmacological control of opioid-induced pruritus: a quantitative systematic review of randomized trials. Eur J Anaesthesiol 2001;18:346-57. (Pubitemid 34603784)
54. Wikstrom B, Gellert R, Ladefoged SD, et al. Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies. J Am Soc Nephrol 2005;16:3742-7. (Pubitemid 46211297)
55. Ko MC, Song MS, Edwards T, Lee H, Naughton NN. The role of central mu opioid receptors in opioid-induced itch in primates. J Pharmacol Exp Ther 2004;310:169-76. (Pubitemid 38812708)
56. Waxler B, Dadabhoy ZP, Stojiljkovic L, Rabito SF. Primer of postoperative pruritus for anesthesiologists. Anesthesiology 2005;103:168-78. (Pubitemid 40949541)
57. Yuan CS, Foss JF, O'Connor M, Osinski J, Roizen MF, Moss J. Efficacy of orally administered methylnaltrexone in decreasing subjective effects after intravenous morphine. Drug Alcohol Depend 1998;52:161-5. (Pubitemid 28529495)
58. Grosman N. Histamine release from isolated rat mast cells: effect of morphine and related drugs and their interaction with compound 48/80. Agents Actions 1981;11:196-203. (Pubitemid 11083772)
59. Tominaga M, Ogawa H, Takamori K. Possible roles of epidermal opioid systems in pruritus of atopic dermatitis. J Invest Dermatol 2007;127:2228-35. (Pubitemid 47258501)
60. Fjellner B. Experimental and clinical pruritus. Studies on some putative peripheral mediators The influence of ultraviolet light and transcutaneous nerve stimulation. Acta Derm Venereol Suppl (Stockh) 1981;97:1-34.
61. Yosipovitch G, Greaves MW, McGlone F, Fleischer AB. Itch: basic mechanism and therapy. New York, NY: Marcel Dekker Inc; 2004.
62. Berg KA, Patwardhan AM, Sanchez TA, Silva YM, Hargreaves KM, Clarke WP. Rapid modulation of micro-opioid receptor signaling in primary sensory neurons. J Pharmacol Exp Ther 2007;321:839-47. (Pubitemid 46762685)
63. Faucher L, Furukawa K. Practice guidelines for the management of pain. J Burn Care Res 2006;27:659-68. (Pubitemid 44450638)
64. Bergasa NV. The pruritus of cholestasis. J Hepatol 2005;43: 1078-88. (Pubitemid 41627995)
65. Bigliardi PL, Bigliardi-Qi M, Buechner S, Rufli T. Expression of mu-opiate receptor in human epidermis and keratinocytes. J Invest Dermatol 1998;111:297-301. (Pubitemid 28354719)
66. Nissen JB, Kragballe K. Enkephalins modulate differentiation of normal human keratinocytes in vitro. Exp Dermatol 1997; 6:222-9. (Pubitemid 27421663)
67. Stein C, Zöllner C. Opioids and sensory nerves. Handb Exp Pharmacol 2009:495-518.
68. Ko MC, Lee H, Song MS, et al. Activation of kappa-opioid receptors inhibits pruritus evoked by subcutaneous or intra-thecal administration of morphine in monkeys. J Pharmacol Exp Ther 2003;305:173-9. (Pubitemid 36373848)
69. Lee H, Naughton NN, Woods JH, Ko MC. Effects of butor-phanol on morphine-induced itch and analgesia in primates. Anesthesiology 2007;107:478-85. (Pubitemid 47329547)
70. Cheng B, Liu HW, Li Q, Fu XB, Sheng ZY, Cao R. [The significance and characteristics of distribution of beta-endorphin and mu-opioid receptors in normal skin and hy-perplastic scar]. Zhonghua Zheng Xing Wai Ke Za Zhi 2008; 24:343-6.
71. Kelly E, Bailey CP, Henderson G. Agonist-selective mechanisms of GPCR desensitization. Br J Pharmacol 2008; 153(Suppl 1):S379-88. (Pubitemid 351340999)